Bookmark and Share
  • Research

  • Research in the division spans basic science to clinical research to population studies. Investigators focused on basic science advances have laboratory space in the Saha Cardiovascular Research Center located in the Biomedical Biological Sciences Building.  Under the direction of Alan Daugherty, PhD, DSc, the Saha CVRC is home to extramurally funded programs in:  

    Atherosclerosis and aneurysm (Alan Daugherty, PhD, DSc; Dennis Bruemmer, MD, PhD; Vicky King, PhD; Hong Lu, MD, PhD; Venkat Subramanian, PhD)

    Cardiac imaging (Steve Leung, MD; Vince Sorrell, MD; Brandon Fornwalt, MD, Phd)

    Bioactive lipid mediators (Andrew Morris, PhD; Susan Smyth, MD, PhD; Ahmed Abdel-Latif, MD, MSPH)

    Platelet function and thrombosis (Zhenyu Li, MD, PhD; Susan Smyth, MD, PhD)

    Stem-cell biology (Ahmed Abdel-Latif, MD, MSPH) 

    Many of our investigators are also engaged in studies to understand the links between obesity and cardiovascular disease.  

    Research is facilitated by state-of-the-art technology for small molecule mass spectrometry (under the direction of Andrew Morris, PhD) and advance cardiovascular imaging.  Indeed, the University of Kentucky houses one of seven institutions in the country to have the state-of-the-art 7-Tesla Clinscan MRI for imaging in preclinical, animal models. Working with world leaders at the University of Virginia (Dr. Frederick Epstein’s laboratory), UK investigators have established advanced mouse cardiac MRI sequences that allow direct quantification of sub-millimeter motion from mouse hearts beating over 500 times per minute. Our Clinscan MRI has a Siemens control system identical to the MRIs used in our cardiology clinic, which facilitates direct translation of our findings in mice into a greater understanding of the human heart.

    Related links

    The division supports a clinical trial section, led by Khaled Ziada, MD, and clinical research manager Tiffany Sandlin, RN. Phase 1 - IV clinical trials are currently under way in structural heart disease, coronary artery disease, heart failure, and electrophysiology.

    Innovative catheter-based approaches to heart and vascular disease have always been a particular strength of our clinical research efforts.  We are currently the only site in Kentucky participating in the Symplicity HTN study of renal denervation for resistant hypertension. 

    Historically, we have been a top enroller in multicenter trials of novel devices for PFO closure, left atrial pressure monitoring (to treat heart failure), and ASD closure. 

    Our involvement in clinical trials makes available innovative treatments that would otherwise not exist in this region of the country. The awarding of a Clinical and Translational Science (CTSA) Program from National Institute of Health places the university in an elite group of 60 biomedical research institutions poised to tackle challenges in medicine and surgery with ground-breaking approaches. 

    Related links



Page last updated: 12/27/2013 9:17:28 AM